Literature DB >> 7040465

Evaluation of fluorescent antinuclear antibody assays, Crithidia luciliae substrate, and single-stranded DNA-binding capacity in diagnosis of four rheumatic diseases.

M Chiang, D Chia, E V Barnett.   

Abstract

Sera from groups of patient with systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis, and progressive systemic sclerosis and normal controls were compared, using different antinuclear antibody assays. Hep-II cells, used as a substrate for the detection of antinuclear antibodies, appeared to be more sensitive than rat liver substrate. In addition, the fluorescent patterns were easier to identify on Hep-II cells. All systemic lupus erythematosus sera with antibodies reactive with kinetoplasts of Crithidia luciliae had binding greater than 43% for single-stranded DNA. Based on the high sensitivity of the Hep-II substrate and the relative specificity of high (greater than 43%) binding for single stranded DNA by sera from patients with systemic lupus erythematosus, it appears that these two tests are most useful in differential diagnosis and for the detection of systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7040465      PMCID: PMC272167          DOI: 10.1128/jcm.15.4.684-687.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Antibodies to DNA in patients with rheumatoid arthritis and juvenile rheumatoid arthritis.

Authors:  C Bell; N Talal; P H Schur
Journal:  Arthritis Rheum       Date:  1975 Nov-Dec

2.  Immunology of DNA. IV. Quantitative aspects of the Farr assay.

Authors:  L A Aarden; F Lakmaker; E R De Groot
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

3.  Double-stranded DNA: an antigen of unique significance.

Authors:  G J Friou
Journal:  J Lab Clin Med       Date:  1978-04

4.  Precipitating antibody to D.N.A. detected by two-stage electroimmunodiffusion. Study in S.L.E. and in rheumatoid arthritis.

Authors:  G D Johnson; J P Edmonds; E J Holborow
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

5.  The role of DNA structure in determining the sensitivity and specificity of anti-DNA antibody tests.

Authors:  E V Barnett
Journal:  J Rheumatol       Date:  1978       Impact factor: 4.666

6.  Detection of antibodies to DNA by radioimmunoassay and immunofluorescence.

Authors:  L A Aarden; F Lakmaker; E R de Groot; A J Swaak; T E Feltkamp
Journal:  Scand J Rheumatol Suppl       Date:  1975

7.  Anti-native DNA detection by the Crithidia luciliae method: an improved guide to the diagnosis and clinical management of systemic lupus erythematosus.

Authors:  S P Ballou; I Kushner
Journal:  Arthritis Rheum       Date:  1979-04

8.  The Crithidia luciliae kinetoplast immunofluorescence test in systemic lupus erythematosus.

Authors:  N G Slater; J S Cameron; M H Lessof
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

9.  Secondary structure in denatured DNA is responsible for its reaction with antinative DNA antibodies of systemic lupus erythematosus sera.

Authors:  B D Stollar; M Papalian
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

10.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06
View more
  2 in total

1.  Comparison of antinuclear antibody and rheumatoid arthritis factor test results between two nearby hospitals.

Authors:  D J Flournoy; S M Qadri; D R Downard; L Woolridge
Journal:  J Natl Med Assoc       Date:  1987-10       Impact factor: 1.798

2.  Assessment of class-specific antibodies against denatured DNA in patients with systemic lupus erythematosus.

Authors:  M Gripenberg; M Leirisalo; E Johansson; G Gripenberg
Journal:  J Clin Immunol       Date:  1985-09       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.